Ignite Creation Date:
2024-05-06 @ 2:51 AM
Last Modification Date:
2024-10-26 @ 11:24 AM
Study NCT ID:
NCT02142868
Status:
NO_LONGER_AVAILABLE
Last Update Posted:
2018-12-21
First Post:
2014-05-16
Brief Title:
Expanded Access Study Of Palbociclib PD-0332991 In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
AN EXPANDED ACCESS STUDY OF PALBOCICLIB IN COMBINATION WITH LETROZOLE AS TREATMENT OF POST-MENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2 NEGATIVE ADVANCED BREAST CANCER FOR WHOM LETROZOLE THERAPY IS DEEMED APPROPRIATE
Status:
NO_LONGER_AVAILABLE
Status Verified Date:
2018-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To provide access to palbociclib to post-menopausal women with HR-positive HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy Canada first-line patients only
Detailed Description:
This study is currently available in Canada only
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None